New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 2, 2013
09:12 EDTPIPPharmAthene announces termination of merger agreement with Theraclone
PharmAthene announced that it has terminated its definitive merger agreement with Theraclone Sciences with consent from Theraclone. The agreement provided for the merger of a wholly-owned subsidiary of PharmAthene into Theraclone in an all-stock, merger-of-equals transaction. Accordingly, PharmAthene has cancelled the Special Meeting of Stockholders scheduled for December 3, 2013 and will pay Theraclone a $1M termination fee.
News For PIP From The Last 14 Days
Check below for free stories on PIP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 10, 2014
10:47 EDTPIP High option volume stocks: KOG PIP IPXL ADP EWH
Subscribe for More Information
April 7, 2014
09:02 EDTPIPPharmAthene receives notice advising company of of SparVax anthrax vaccine
PharmAthene announced that it has received notice from the Department of Health and Human Services, Biomedical Advanced Research and Development Authority, advising the company of its decision to de-scope the current SparVax anthrax vaccine contract through a partial termination for convenience. BARDA will provide additional guidance to PharmAthene on the contractual changes, following which PharmAthene will evaluate its options with respect to its SparVax program. PharmAthene has been developing SparVax to address a requirement for a modern anthrax vaccine based on state-of-the-art vaccine technology. Phase 1 and Phase 2 clinical trials involving 770 healthy subjects have demonstrated that SparVax appears to be well tolerated and capable of producing an immune response in humans.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use